FDA rejects Cempra's antibiotic for pneumonia, shares sink
(Reuters) - Cempra Inc said on Thursday the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia (CABP), citing inadequate data on the drug's impact on the liver and manufacturing issues.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Bacterial Pneumonia | Food and Drug Administration (FDA) | Health | Liver | Pneumonia | Urology & Nephrology